We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Innovative Technology Extrapolates Coronary Risks from ECG signals

By HospiMedica International staff writers
Posted on 11 Apr 2011
A chemical and radiation-free procedure offers completely noninvasive cardiac testing using an integrated mathematical power estimate to assist physicians in the diagnosis of coronary artery disease (CAD).

The Multifunction CardioGram (MCG) works by sampling a signal from two left ventricular electrocardiogram (ECG) leads (V5 and II) and performing a series of digital signal analysis operations; the operations produce a sequence of indexes, which quantify abnormalities in the mathematically transformed electro-cardiac data. More...
This information is transferred via the internet to a data center for interpretation, where it is compared to a database of over 40,000 patients. A numeric score is then assigned based on this analysis, representing the likelihood and severity of CAD. Multiple studies have shown that the MCG assists in accurate detection of significant CAD, with improved specificity and negative predictive values.

The MCG test session and subsequent analysis can typically be completed within 10 minutes, making it practical as part of routine care and screening, as well as in urgent care situations for patients with acute symptoms of cardiac distress. Additionally, since the MCG test session involves only a surface resting ECG, and does not share the risks or contraindications of other diagnostic procedures such as stress tests, cardiac magnetic resonance imaging (MRI), or nuclear perfusion imaging, it is a viable option for a wider range of patients than many other procedures. The Multifunction CardioGram was developed by Premier Heart (Port Washington, NY, USA).

"Using a computational systems analysis approach we, as physicians, now have a method that analyzes and compares raw electrocardiac data to help identify significant CAD,” said Joseph Shen, MD, founder of Premier Heart and the lead developer of the MCG. "This score is reported back to physicians within minutes to aid in detection and diagnosis in a point of care setting.”

"The evidence shows that this device can identify early onset coronary artery disease before clinical presentation, and this provides opportunity for aggressive preventative measures for a first myocardial infarction due to silent myocardial ischemia,” said Joseph Hickey, MD, of the Heritage Medical Center (Shelbyville, TN, USA). "The MCG analysis is the most accurate current means for detection of heart disease noninvasively.”

Related Links:

Premier Heart




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.